Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

53.81

+6.74

(+14.32%)

As of 12:41PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Engulfing Line (Bullish)

View all chart patterns

Performance Outlook

Previous Close	47.07
Open	47.06
Bid	53.51 x 800
Ask	53.49 x 2200
Day's Range	46.19 - 54.06
52 Week Range	41.33 - 277.80
Volume	3,828,929
Avg. Volume	4,625,400

Market Cap	4.204B
Beta (5Y Monthly)	1.58
PE Ratio (TTM)	N/A
EPS (TTM)	-17.51
Earnings Date	Aug 03, 2022 - Aug 08, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	158.67

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NVAX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Novavax, Inc.
Daily – Vickers Top Buyers & Sellers for 04/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
2 months agoArgus Research

All

MarketWatch
White House steps up effort to provide antiviral access to more Americans as cases start to stabilize in Northeast
The White House on Thursday announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S., cautioning that COVID-19 cases are likely to continue to climb over the summer travel season.
- Morning Update: Gas Prices, COVID Antiviral Treatment Coming To MN & More
  CBS-Minneapolis
- Coronavirus tally: White House unveils more steps to make antiviral Paxlovid more accessible across U.S.
  MarketWatch
MarketWatch
The FDA’s decision on the Novavax COVID-19 vaccine could come in weeks
The company's protein-based shot has been authorized or approved in several other countries, including the U.K. and Singapore.
Motley Fool
Why Wall Street Thinks Novavax Is a No-Brainer Stock to Buy Right Now
Novavax (NASDAQ: NVAX) is very late to the party in entering the COVID-19 vaccine market. Wall Street analysts are extremely pessimistic about the stock. Novavax definitely is late in entering the COVID-19 vaccine market and still hasn't won authorization for its vaccine in the U.S. Novavax's shares really have sunk like a brick since the fourth quarter of 2021.